Blue Horseshoe Stocks: FRO Review & More

Frontline Ltd. FRO

FRO has definitely turned out to be one of our biggest success stories of the past several weeks. Just to refresh people’s memories, we caught this play coming off of some of its lowest prices of the year back on December 1st. Our observed low on FRO was 1.33 at that time, and in two huge upward moves the stock has traversed quite a bit of territory since then.

Yesterday FRO achieved a high of 5.05, which marks a total increase of 280% in just under six weeks! As we did after the initial push, we could now see a possible dip-and-rip scenario. We’ll remain interested provided the stock maintains support at or above the $3-area on the pullback.

As we can see on the chart above, there is a potential Golden Cross in the making, and with tens of millions of barrels of crude to be held on tankers over the next few months given the current oil landscape, this may not be the last time we point to big moves from FRO.

BARCHART.COM is currently giving FRO a “100% Buy” rating.

Twitter, Inc. TWTR – Options

Following up on one of the options ideas we were mulling over on TWTR last week; the TWTR February $40 Calls. When we first mentioned them last Wednesday (Saw a low of 2.15), we mentioned that they “could be in line for significant gains if TWTR continues to recover off of recent lows” and we did in fact see some substantial movement.

Those Feb. $40’s hit a high of 3.70 during the day yesterday, for an overall increase of 72% in a span of just four sessions! Even further gains could be forthcoming provided TWTR continues the current trend, so we’ll want to reserve it a slot on our watchlist as we head into mid-week.

Extended Watchlist:
NLST, CTIC, NSPR, RSH, ELX, ANV

Blue Horseshoe Stocks: Special Report on DKTS

Top Shelf Brands Holding Corp. DKTS

To kick things off this week, we’ve got a new interest operating in the premium spirits business, a market sector to which we have not devoted our attention in quite some time.

DKTS is a symbol that is new to our reports today as well as being fairly new overall, with just a couple months’ trading history on the books (Prior to November 2014, Top Shelf traded as TEMN). It has shown its resilience in recent sessions, but let’s take a look at what the company has going on from a business standpoint before diving into the specifics of the chart.

One particular advantage Top Shelf currently has is an active federal license to both import and supply alcoholic beverages in the US. The company’s line of products includes three offerings at the moment; a high-end tequila, a specialty liqueur, and a premium imported Champagne.

DZIAC Liqueur is a blend of vodka, pomegranate, lychee, dragonfruit, and mezcal (alcoholic beverage made from a specific strain of agave), and Arcangel is the name of Top Shelf’s variety of Champagne, which is of course imported from France.

Perhaps the most interesting is the Besado Tequila brand, which really takes traditional tequila to the next level through the addition of herbal stimulants. On top of thrice-distilled tequila made from aged blue agave, Besado contains Damiana root, which has been used for centuries in Meso-America for increased energy and sexual vigor, Maca, a vitality-inducing tuber native to the Andes Mountains, and ginseng. Two varieties will be available as pictured above.

Those three are the preliminary brands in DKTS‘s repertoire, with more expected to be added upon the successful launch of those products.

According to a recent press release, DKTS has teamed up with an experienced brand development firm to speed up the process of its beverages getting to market. Big Tent Marketing has worked on such well-known labels as Hpnotiq Liqueur, Rhythm Liqueur, Maker’s Mark Bourbon and more, and should be a good addition to DKTS’s efforts.  >>> READ PR

CHART:

Getting to the DKTS Chart, we’ve got a number of ripe indicators as the price has rebounded off of a recent low of .001. The first area of resistance on the chart is sitting at .0021, and beyond that, the 200DMA  (.0032). Being a stock that’s trading in the sub-penny range, we are well aware of the types of exponential gains that can be realized, and there has been some good momentum flowing through DKTS in recent sessions, so this play is high on our watchlist to start the week.

You can also take a look at the video chart we put together for DKTS this morning:

For More Info Visit:
DrinkTopShelf.com

Blue Horseshoe Stocks: BIND Recap & More

BIND Therapeutics, Inc. BIND

BIND cropped up on our premarket scanner yesterday in the wake of a post-market PR on Wednesday afternoon, and it put forth a solid move early in the session. It traded as low as 7.40 at the open, and we then witnessed a significant 36% spike to the high-of-day at 10.04.

That initial run was fueled by the release of positive Phase-2 results from one of the company’s many cancer treatments currently in various trial phases, and additionally, an update on guidance for 2015.  >>> READ PR

According to the CEO, BIND expects 2015 “to be a particularly active period” with regard to the development of its many products, so this will be a play that we’ll want to monitor more closely moving forward.

Toward the end of the session yesterday BIND pulled back, and is gapping once again in the pre-market, so we have our eyes peeled for any potential bounce action that could be used in our favor.

Twitter, Inc. TWTR – Options

We’ve also got to update everyone on the options trading idea we put forth earlier this week for TWTR. We mentioned an interest in the Weekly $38 and $39 Calls, and each set of contracts showed us a huge spike during yesterday’s session.

The $38’s traded in a range from .23-1.22, for a chance at monstrous gains of up to 430%, while the $39’s did even better as they ripped from .09 to a high of .54, a move totaling 500%

We also wanted to remind readers of the long-term options idea for TWTR we mentioned in the same report. The February $40 Calls could be in line for significant gains if TWTR continues to recover off of recent lows in the $35-36 range.

Extended Watchlist:
AGEN, CERE, ARNA, SD, NVAX, CARA